Roth Capital Sees Prelim. Q2 Revenue Numbers from Ligand (LGND) as Just the Beginning of More Success to Come
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy with a target price of $92. Thursday morning, Ligand said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
